Profile

New User

New to Graphy Publications? Create an account to get started today.

Registered Users

Have an account? Sign in now.

How to Cite | Author Information | Publication History
International Journal of Diabetes & Clinical Diagnosis Volume 3 (2016), Article ID 3:IJDCD-117, 5 pages
http://dx.doi.org/10.15344/2394-1499/2016/117
Review Article
Liraglutide is a Perioperative Therapeutic Option for Patients with Type 2 Diabetes that Undergo Elective Surgery

Naoko Katagiri1, Ikue Kigawa2, Yumiko Yahara1, Yohei Ueda1, Kumiko Hamano2 and Shizuka Kaneko1*

1Division of Diabetes/Endocrinology/Lifestyle-Related Disease, Takatsuki Red Cross Hospital, Japan
2Kanto Rosai Hospital, Japan
Dr. Shizuka Kaneko, Department of Diabetes/ Endocrinology/Life-related disease, Takatsuki Red Cross Hospital, Japan; E-mail: skayamoe@takatsuki.jrc.or.jp
04 March 2016; 13 June 2016; 15 June 2016
Katagiri N, Kigawa I, Yahara Y, Ueda Y, Kaneko S, et al. (2016) Liraglutide is a Perioperative Therapeutic Option for Patients with Type 2 Diabetes that Undergo Elective Surgery. Int J Diabetes Clin Diagn 3: 117. doi: http://dx.doi.org/10.15344/2394-1499/2016/117
© 2016 Katagiri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

  1. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, et al. (2009) Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360: 1283-1297. View
  2. Bailey CJ, Tahrani AA, Barnett AH (2016) Future glucose-lowering drugs for type 2 diabetes. Lancet Diabetes Endocrinol 4: 350-359. View
  3. Schwartz S, DeFronzo RA (2013) Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists! Diabetes Care 36: 2107-2111. View
  4. Umpierrez GE, Korytkowski M (2013) Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type2 Diabetes? Insulin therapy has proven itself and is considered the mainstay of treatment. Diabetes Care 36: 2112-2117. View
  5. Butler PC, Elashoff M, Elashoff R, Gale EA (2013) A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care 36: 2118-2125. View
  6. van Wezel HB, Zuurbier CJ, de Jonge E, van Dam EW, van Dijk J, et al. (2006) Differential effects of a perioperative hyperinsulinemic normoglycemic clamp on the neurohumoral stress response during coronary artery surgery. J Clin Endocrinol Metab 91: 4144-4153. View
  7. Christensen M, Bagger JI, Vilsbøll T, Knop FK (2011) The alpha-cell as target for type 2 diabetes therapy. Rev Diabet Stud 8: 369-381. View
  8. Seufert J, Gallwitz B (2014) The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab 16: 673-688. View
  9. McCormick LM, Heck PM, Ring LS, Kydd AC, Clarke SJ, et al. (2015) Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus. Cardiovasc Diabetol 14: 102-114. View
  10. Mima A (2016) Incretin-Based Therapy for Prevention of Diabetic Vascular Complications. J Diabetes Res 2016: 1379274. View
  11. de Wit HM, Vervoort GM, Jansen HJ, de Galan BE, Tack CJ (2016) Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial. J Intern Med 279: 283-292. View
  12. Perna S, Guido D, Bologna C, Solerte SB, Guerriero F, et al. (2016) Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study. Aging Clin Exp Res 26749118. View
  13. Meier JJ, Rosenstock J, Hincelin-Méry A, Roy-Duval C, Delfolie A, et al. (2015) Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: A randomized, open-label trial. Diabetes Care 38:1 263-1273. View
Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version
Privacy Policy | Copyright & Permissions
Copyright © 2013-2024 Graphy Publications, All Rights Reserved.